38 results about "Weight-loss drugs" patented technology

A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and/or administering a weight loss drug.

A method for treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and/or administering a weight loss drug.

The invention relates to the field of pharmaceutical chemistry and relates to a method for preparing (R)-8-chlorine-1-methyl-2,3,4,5-tetrahydro-1H-3-benzodiazepine hydrochloride (Lorcaserin) and an intermediate of Lorcaserin. (R)-8-chlorine-1-methyl-2,3,4,5-tetrahydro-1H-3-benzodiazepine hydrochloride (Lorcaserin) which is an active material of a weight-loss drug is prepared from epoxy propane and p-chlorophenyl ethylamine serving as starting raw materials through the steps of ring opening, chlorination, cyclization, tartaric acid splitting, dissociation, salification and the like.

The invention provides fucan sulfate and application of low-molecular-weight fucan sulfate in preparation of blood fat reduction and weight loss drugs and health care products. The fucan sulfate and the low-molecular-weight fucan sulfate can be used for remarkably suppressing aggregation of triglyceride and cholesterol of liver cells when concentration is larger than 50 micrograms per milliliter, and the fucan sulfate and the low-molecular-weight fucan sulfate can be used for effectively reducing the level of TG, TC and LDL in blood, increasing the level of HDL in the blood and obviously reducing weight and the content of abdominal fat. As is provided through experiments, FS and LFS have a good function of reducing blood fat and losing weight. The raw materials come from alga and have the advantages of being rich in resource, low in cost, high in safety performance and the like, the situation that the high blood fat and obesity state can be remarkably improved is proved both in a body and outside the body, and a new way is provided for developing the kind of drugs.

An orally disintegrating tablet which can be chewed or disintegrated by contact with saliva and containing weight-loss drugs for weight control in humans, especially in children and adolescents, is disclosed.

The invention provides a lotus leaf dietary therapy method for reducing fat and losing weight. The method is characterized in that the lotus leaf is used as the major raw material. The method comprises the following steps of preparing a piece of lotus leaf (dried and fresh both ok), 20g of cassia occidentalis, 2 to 3 parts of hawthorn, 15g of orange peel (dried and fresh both ok), 10g of lycium barbarum, and 6g of aloe; crushing the washed lotus leaf; washing hawthorn and removing beard; washing cassia occidentalis and aloe and decocting for 30 minutes with 1,000ml of water, wherein the decocting is performed with big fire firstly until boiling and then slowed down with soft fire; filtering the medicinal liquor after decocting; adding polished round-grained rice, orange peel and lycium barbarum to the decocted medicinal liquor; and slowly decocting with soft fire until thicken congee is produced. The thicken congee is taken two to three times once a week and is suitable for all people. The lotus leaf dietary therapy method can solve the problem of taking weight-loss drug or giving an injection of the traditional method and is suitable for people suffering from high fat caused by diet and the fat crowd.

The invention belongs to the field of pharmaceutical preparation, and particularly provides an application of berberine in preparation of a medicine used for inhibiting autophagy of adipocyte and a medicine used for treating obesity. According to the application, C3H10T1/2 cell is cultured and induced to be differentiated into mature adipocyte, then the test for the impact of berberine to the mature C3H10T1/2 adipocyte autophagy marker protein LC3 and an autophagy substrate P62, and the test for detecting the C3H10T1/2 flat autophagy flux variation through chloroquine serving as a lysosomal inhibitor are performed, and the variation of the quantity of autophagosome can be observed through a transmission electron microscope; the results of various tests show that the berberine can effectively inhibit the autophagy of C3H10T1/2 adipocyte and provides theoretical basis for clinically reasonably applying the berberine to the treatment of obese patients; in addition, the berberine also can be applied to the preparation of the medicine for inhibiting the autophagy of adipocyte.

Weight loss methods and systems are described. In one embodiment, behavior modification program data indicating participation in a weight loss behavior modification program is recorded. Drug therapy program data indicating drug fulfillment of a weight loss drug therapy program drug is recorded, in which the drug fulfillment of the weight loss drug therapy program drug occurs after participation in the weight loss behavior modification program. Whether a weight loss surgical program criterion has been met is determined based on analysis of the behavior modification program data and the drug therapy program data. The weight loss surgical program criterion is based on the participation in the weight loss behavior modification program and the drug fulfillment of the weight loss drug therapy program drug. A surgical weight loss program approval is generated based on a determination that the surgical weight loss program criterion has been met. Additional methods and systems are disclosed.

The invention discloses a method for synthesizing weight loss drug orlistat key intermediate. According to the method disclosed by the invention, n-dodecanal is utilized as a beginning raw material, orlistat intermediate compound (9) is prepared through multiple steps of reaction, and finally, orlistat can be prepared through two steps of known reaction of chiral hydroxyl deprotection reaction andmistsunobu reaction. A synthesizing strategy of the method disclosed by the invention is a typical linear strategy, a route design is simple and reasonable, an operation technology is convenient, reaction conditions are moderate, steps are few, a product yield is high, production cost is remarkably reduced, and the method is suitable for industrial preparation.

The present invention relates to a formula of weight-loss medicine, and the raw materials in the formula are respectively composed by weight percentage: Astragalus 5-15%, Angelica 1-5%, Poria 1-10%, Atractylodes macrocephala 5-15%, Alisma 3-9 %, Plantago 2‑3%, Amomum 1‑5%, Yam 11‑19%, Dogwood 5‑7%, Morinda officinalis 3‑5%, Cuscuta 3‑5%, Cinnamon 1‑5%, Rehmannia glutinosa Huang 5‑10%, Safflower 1‑1.5%, Epimedium 4‑5%, Junchen 2‑4%, Radix Polygoni Multiflori 0.4‑0.6%, Fructus Rosa 1‑2%, Polygonatum 2‑4%, Raw Hawthorn 1‑3%, the slimming drug of the present invention has the effect of stably lowering blood pressure without rebounding and stabilizing blood pressure for a long time. It does not need long-term medication, has no drug resistance, is safe and has no side effects, and is suitable for a wide range of people. It is a caring medicine for ordinary people.

The invention discloses a Chinese medicinal material extract with the function of reducing weight and a preparation method of the Chinese medicinal material extract. The Chinese medicinal material extract raw material is prepared from stems and leaves of twigs of prinsepia utilis royle. The preparation method includes the steps of step one, raw material selection; step two, pretreatment of raw materials; step three, baking of the raw materials; step four, raw material rolling; step five, raw material drying; and step six, extract preparation. According to the Chinese medicinal material extractwith the function of reducing weight and the preparation method of the Chinese medicinal material extract, preparation of the extract from the prinsepia utilis royle is simple and easy to carry out,and the cost is low. According to a C57BL/6J mouse model experiment, the weights of obese mice can be effectively reduced, the body fat content of the obese mice induced by high-fat diet can be reduced, the lipid level of the obese mice induced by the high-fat diet can be effectively regulated, and LPL and PL levels in serum of the obese mice can be effectively regulated. With the effect of significant weight loss, the Chinese medicinal material extract can reduce fat tissue hypertrophy, is used as raw materials of weight-loss drugs, health products or food to help obese people lose weight andreduce body fat.

The invention relates to an extraction method of flammulina velutipes sporocarp dietary fiber, which comprises the following steps of: cleaning flammulina velutipes sporocarp, performing leaching with ethanol, airing residues, performing leaching with a 2-8% sodium hydroxide solution at 60-80 DEG C, performing filtering, washing the filter residues to be neutral, and performing drying to obtain the flammulina velutipes sporocarp dietary fiber. According to the invention, a rat obesity model is established by using a high-fat feed; the weight, the Lee's index, the BMI and the visceral organ index of a rat are measured; and pathological changes of adipose tissues and livers of the rat are observed through an HE staining method. The weight reduction effect of the flammulina velutipes sporocarp dietary fiber is comprehensively evaluated through the detection indexes. Experimental results prove that the flammulina velutipes sporocarp dietary fiber can effectively reduce the weight, the Lee's index, the BMI and the visceral organ index of the rat and relieve visceral organ injury caused by modeling, and has no toxic or side effect, so that the flammulina velutipes sporocarp dietary fiber disclosed by the invention can be used for preparing health care products or drugs for treating/preventing obesity.

The invention discloses a detoxifying and beautifying weight loss drug which is characterized in that the traditional Chinese medicine is prepared from the following raw materials in parts by weight: 8-15 parts of wine steamed rheum officinale, 8-15 parts of gardenia jasminoides, 10-16 parts of honeysuckle, 10-14 parts of broadleaf holly leaf, 8-12 parts of ephedra, 8-12 parts of divaricate saposhnikovia root, 10-20 parts of schizonepeta, 10-20 parts of mint, 10-20 parts of radix scutellariae, 10-20 parts of ligusticum wallichii, 15-20 parts of liquorice, 6-12 parts of talc, 10-15 parts of purple sweet potato, 10-14 parts of bighead atractylodes rhizome, 10-14 parts of poria cocos, 10-14 parts of pericarpium arecae, 8-10 parts of immature bitter orange, 9-12 parts of semen brassicae and 8-10 parts of almond. The detoxifying and beautifying weight loss drug is good in weight loss effect and does not have a side effect, and the raw materials come from conventional medicinal materials and are low in price.

The invention discloses a use of a GLP-1 mutant in preparation of weight-loss drugs. The GLP-1 mutant is obtained by mutation of amino acid sites on the basis of wild-type GLP-1, and has an amino acid sequence shown in SEQ ID NO:1. The GLP-1 mutant can effectively reduce body weight, fat-body ratio and other indicators, can be used for reducing body weight of obesity people, and has broad application prospects.

The invention belongs to the technical field of vaccines, and discloses a recombinant protein for weight loss, a vaccine and a construction method thereof. The vaccine for weight loss is recombinant protein 1; a protein sequence of the recombinant protein 1 is SEQ ID NO: 1; and a gene DNA sequence of the recombinant protein 1 is SEQ ID NO: 2. The body weight and fat content of nutritional obese mice are effectively reduced by immunizing the recombinant protein with a unique structure and neutralizing somatostatin secreted in the body to relatively increase the secretion amount of growth hormone, so that the problems of long-term use, large adverse reactions, high treatment cost and the like of weight loss drugs in the prior art are solved.